ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Sunday, October 26, 2025

10:30AM-12:30PM: Abstract Number: 0164

Online Patient Survey on the Impact of Extreme Weather Events on Autoimmune and Rheumatic Diseases

(0145–0174) Epidemiology & Public Health Poster I

10:30AM-12:30PM: Abstract Number: 0253

Ophthalmology Screening for Asymptomatic Uveitis in Sarcoidosis Patients: A Single-Center Investigation

(0233–0279) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

10:30AM-12:30PM: Abstract Number: 0183

Optimizing the Clinical Application of Rheumatology Guidelines Using Large Language Models: A Retrieval-Augmented Generation Framework Integrating EULAR and ACR Recommendations

(0175–0198) Health Services Research Poster I

10:30AM-12:30PM: Abstract Number: 0439

Osteoarthritis and Other Degenerative Musculoskeletal Disorders Are Common and Often Associated with Active Inflammation in Difficult-to-Treat Rheumatoid Arthritis: A Cross-Sectional Cohort

(0430–0469) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0140

Outcome Of Patients With Non-Criteria Manifestations Of Primary Antiphospholipid Syndrome Treated With Immunosuppressants -A Single Centre Study

(0115–0144) Antiphospholipid Syndrome Poster

10:30AM-12:30PM: Abstract Number: 0411

Outcomes in Juvenile Idiopathic Arthritis Based on Geographic Region in the Pediatric Rheumatology Care and Outcomes Improvement Network Registry

(0387–0429) Pediatric Rheumatology – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0416

Outcomes Of Children with Juvenile Idiopathic Arthritis Receiving Biological Disease-Modifying Anti-Rheumatic Drugs: Retrospective Analysis of A Real-World Experience From A Resource-Limited Setting

(0387–0429) Pediatric Rheumatology – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0492

Outcomes of Total Knee Replacement in Patients with Rheumatoid Arthritis: A National Inpatient Sample Database Analysis

(0470–0505) Rheumatoid Arthritis – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0397

Paediatric uveitis – Retrospective comparison of cataract surgery outcomes with or without intraocular lens implantation from two tertiary centres in United Kingdom

(0387–0429) Pediatric Rheumatology – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0199

Pain Phenotypes and Social Determinants of Health in Chronic Chikungunya Arthritis: A Cross-Sectional Study

(0199–0209) Infection-related Rheumatic Disease Poster

10:30AM-12:30PM: Abstract Number: 0561

Patient Characteristics and Treatment Patterns of Traditional and Advanced Therapies Prior to First Secukinumab Intravenous (IV) Administration in Patients with Spondyloarthritis (SpA) in US Real-World Clinical Settings

(0554–0592) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0153

Patient Experience and Implementation of an Electronic Patient-Reported Outcome Measures (ePROM) System for Remote Monitoring in BIOBADASER

(0145–0174) Epidemiology & Public Health Poster I

10:30AM-12:30PM: Abstract Number: 0370

Patient Preferences for Treatments of Rheumatoid Arthritis: A Discrete Choice Experiment Evaluating Preference for Advanced Drug Therapies and Neuroimmune Modulation Device

(0357–0386) Patient Outcomes, Preferences, & Attitudes Poster I

10:30AM-12:30PM: Abstract Number: 0175

Patient Satisfaction with a New Patient Video Triage Program

(0175–0198) Health Services Research Poster I

10:30AM-12:30PM: Abstract Number: 0594

Patients with SLE Have an Increased Bisphenol A Methylation Score Linked to SLE Risk Genes and Immune Response Pathways

(0593–0640) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].